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Letters to the EditorTo the Editor:
We appreciate the interest of Dr. Thalheimer and Dr. Burroughs
in our study [1]. It is true that the baseline characteristics of
our patients showed a slightly greater percentage of previous
spontaneous bacterial peritonitis, variceal bleeding, and hepato-
cellular carcinoma in the saline arm, but without signiﬁcant dif-
ferences. We agree that the presence of renal failure in the saline
group could be a confounding factor that might help explain the
differences in survival between both groups. However, the MELD
score, used to predict survival, had no differences in both arms.
The ﬁndings in survival were, as is reﬂected in the article, a
secondary endpoint. The study was not designed to evaluate mor-
tality. Nevertheless, we thought that the results had sufﬁcient
clinical relevance to be highlighted. The development of hepatic
encephalopathy in advanced cirrhosis has been related to a worse
prognosis and high mortality [2]. It is possible that the presence
of hepatic encephalopathy identiﬁes a group of patients that can
beneﬁt from the administration of albumin.
We agree that the hypothesis should be tested in subsequent
studies with an adequate design and optimized sample size to
accomplish this goal. The current study sets the basis for explor-
ing the value of albumin in advanced cirrhosis identiﬁed by the
development of hepatic encephalopathy.
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manuscript.Fatigue and liver transplantation in patients
with primary biliary cirrhosis
To the Editor:
We read with great interest the paper of Carbone et al. [1] on fati-
gue in patients with primary biliary cirrhosis (PBC) and the role of
liver transplantation. They performed a prospective, longitudinal
study investigating fatigue in 49 adult cirrhotic patients with PBC
at listing and at 6, 12, and 24 months after transplantation. They
found that fatigue scores, as assessed by means of the PBC-40
questionnaire, improved substantially following transplantation
but remained higher compared to community controls two years
post-transplant [1]. In all, 89% of patients had moderate to severe
fatigue before transplantation, which was also true for 48% and
44% at one and two years post-transplant respectively [1].
We have recently reported that although fatigue improves fol-
lowing transplantation in unselected cirrhotic patients, 37% are
physically fatigued 1 year post-transplant [2], which is in accor-
dance with previous studies [3,4]. In this prospective longitudinal
study [2] no patients with hepatic encephalopathy grade >I were
included as they could not complete the study questionnaires.
Encephalopathy was assessed clinically (West-Haven criteria)
and by means of the number connection tests A and B [2]. We
found that fatigue severity in unselected cirrhotic patients wors-
ened with worsening encephalopathy (from none to minimal and
overt) [2]. Only 12 patients included in this paper had PBC (med-
ian age 54 (interquartile range 39–60); 9 female) and 10 reached
1 year post-transplant (1 patient died on the transplant list and
another during the ﬁrst post-transplant year). Fatigue was
assessed by means of the fatigue impact scale, a 40-item ques-
tionnaire, which has been validated in PBC [5]. Fatigue data from
these patients (not reported separately in the initial report) in
comparison to non-PBC cirrhotic patients are shown in Table 1.
Fatigue scores across all domains did not differ signiﬁcantly
between the two groups neither pre- nor post-transplant
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